The need for routine bleomycin test dosing in the 21st century

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Bleomycin is an antineoplastic agent used in cancer treatment.
• Hypersensitivity reactions, including anaphylaxis, can occur with bleomycin administration.
• The utility of test dosing for bleomycin-induced reactions is debated.

Purpose of the Study:

• To evaluate the clinical evidence supporting the routine use of bleomycin test dosing.
• To assess the predictive value of test doses for hypersensitivity reactions.

Main Methods:

• A comprehensive literature search was conducted using MEDLINE, including review articles, case reports, and clinical trials.
• Data were gathered from 1966 to July 2005, utilizing keywords such as 'bleomycin,' 'test dose,' 'anaphylactic reactions,' and 'hypersensitivity.'
• Information was supplemented by an unpublished survey, manufacturer data, and internet resources.

Main Results:

• Acute hypersensitivity reactions to bleomycin occur in approximately 1% of lymphoma patients and less than 0.5% of solid tumor patients.
• Reactions manifest as fever, chills, hypotension, and potentially fatal cardiovascular collapse.
• No correlation was found between bleomycin dose and the onset or severity of these reactions.

Conclusions:

• The incidence of severe bleomycin hypersensitivity reactions is low but potentially life-threatening.
• Routine test dosing does not reliably predict the occurrence of these reactions.
• Continuous patient monitoring for signs of hypersensitivity during bleomycin administration is crucial.